POST LEONARD E
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 11, 2026
QURE shares fall after Huntington data update and Barclays downgrade. Cedar Grove Capital released its Q3 2026 portfolio update, noting QURE holdings. The stock fell 5.9% after Huntington's gene therapy data was updated, prompting a Barclays downgrade to equal‑weight and a new price target of $28. The move comes amid a broader market pullback, with the shares near a 17.1 RSI and a support level of $44.06.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 25, 2026
FLGT compared to PRPO in cancer diagnostics sector. A recent article compares Fulgent Genetics with PrecisionDx, evaluating which cancer diagnostics stock has more potential. This comparison highlights FLGT's position within the specialized diagnostics market. The stock is currently trading near the average analyst target price of $19.00, which sits within its 52-week range.
Transaction History
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 9/15/2026 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $73K | 9/15/2026 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 8/14/2026 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $75K | 8/14/2026 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 7/15/2026 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $71K | 7/15/2026 | View on chart |
| CGON | ▲ Buy | Option Exercise | 5,000 | $3K | 6/24/2026 | View on chart |
| CGON | ▼ Sell | Open Market | 5,000 | $350K | 6/24/2026 | View on chart |
| CGON | ▲ Buy | Option Exercise | 5,000 | $3K | 6/22/2026 | View on chart |
| CGON | ▼ Sell | Open Market | 5,000 | $325K | 6/22/2026 | View on chart |
| QURE | ▼ Sell | Open Market | 1,993 | $54K | 6/11/2026 | View on chart |
| QURE | ▲ Buy | Grant | 7,550 | $0 | 6/10/2026 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 6/4/2026 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $55K | 6/4/2026 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 11/17/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $41K | 11/17/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 10/13/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $43K | 10/13/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 5,000 | $3K | 9/30/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 5,000 | $200K | 9/30/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 9/15/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $35K | 9/15/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $28K | 9/3/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 9/3/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 2,000 | $1K | 7/17/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 2,000 | $56K | 7/17/2025 | View on chart |
| QURE | ▼ Sell | Open Market | 2,112 | $31K | 6/20/2025 | View on chart |
| QURE | ▲ Buy | Grant | 7,970 | $0 | 6/11/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 5/21/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $28K | 5/21/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 4/28/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $31K | 4/28/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $28K | 3/17/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 3/17/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 2/18/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $29K | 2/18/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 1/13/2025 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $30K | 1/13/2025 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 12/16/2024 | View on chart |
| CGON | ▼ Sell | Open Market | 1,000 | $29K | 12/16/2024 | View on chart |
| CGON | ▲ Buy | Option Exercise | 1,000 | $600 | 12/6/2024 | View on chart |
| CGON | ▼ Sell | Open Market | 750 | $26K | 12/6/2024 | View on chart |
| CGON | ▼ Sell | Open Market | 250 | $9K | 12/6/2024 | View on chart |
| QURE | ▲ Buy | Grant | 8,080 | $0 | 6/19/2024 | View on chart |
| QURE | ▼ Sell | Open Market | 2,222 | $11K | 6/13/2024 | View on chart |
| QURE | ▼ Sell | Open Market | 2,291 | $43K | 6/16/2023 | View on chart |
| QURE | ▲ Buy | Grant | 8,700 | $0 | 6/13/2023 | View on chart |
| QURE | ▼ Sell | Open Market | 389 | $8K | 2/27/2023 | View on chart |
| FLGT | ▲ Buy | Grant | 8,000 | $0 | 8/1/2022 | View on chart |
| QURE | ▲ Buy | Grant | 9,080 | $0 | 6/15/2022 | View on chart |
| QURE | ▼ Sell | Open Market | 795 | $13K | 2/28/2022 | View on chart |
| QURE | ▲ Buy | Grant | 1,534 | $0 | 2/24/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
CG Oncology appoints Isabel Kalefonos as Chief Commercial Officer
CG Oncology announced the appointment of Isabel Kalefonos as its new chief commercial officer. The hire adds experienced biopharmaceutical leadership as the company prepares for a possible bladder cancer product launch. The addition may strengthen the commercial strategy ahead of upcoming market activities.
CG Oncology appoints Isabel Kalefonos as Chief Commercial Officer. CG Oncology announced the appointment of Isabel Kalefonos as its new chief commercial officer. The hire adds experienced biopharmaceutical leadership as the company prepares for a possible bladder cancer product launch. The addition may strengthen the commercial strategy ahead of upcoming market activities.